Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...

Alzheimer’s Society has warned urgent action is needed to address the projected 51 per cent rise in dementia cases across ...

“Even in individuals who had not yet developed kidney disease, we could see that kidney function was linked to brain atrophy.

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, ...

The headset, developed by researchers at Cornell University in New York, could help reveal how the brain navigates and ...

Overview: In Uganda alone, frequent FMD outbreaks have resulted in losses amounting to millions annually. Between 2015 and ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Intra-Cellular’s clinical-stage pipeline is promising, with pipeline agents under development for a wide range of neurological indications.

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds. Get Real-Time ...